Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
Launched by ERASMUS MEDICAL CENTER · Mar 23, 2021
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying two different methods for treating a serious condition called walled-off necrosis (WON), which can occur in patients with severe acute pancreatitis. The trial compares traditional endoscopic techniques to a new device called the EndoRotor® Resection System. The goal is to see which method is more effective in removing necrotic (dead) tissue from the pancreas and improving patient outcomes.
To participate, patients must have symptoms related to pancreatic necrosis and should have already undergone a procedure to drain the fluid. They must be able to tolerate repeated endoscopic procedures and provide written consent to be part of the study. Participants can expect to be randomly assigned to one of the two treatment methods and will have follow-up assessments to monitor their progress. It's important to know that certain conditions, like specific blood vessel issues or being pregnant, may exclude someone from participating in this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with symptomatic pancreatic necrosis due to acute pancreatitis that have an indication to undergo endoscopic necrosectomy after having undergone EUS-guided drainage.
- • a. Stent must be in place for a minimum of 2 days prior to the DEN procedure.
- • Patients who can tolerate repeat endoscopic procedures.
- • Subjects with the ability to understand the requirements of the study, who have provided written informed consent, and who are willing and able to return for the required follow-up assessments.
- • ASA classification \< 5.
- Exclusion Criteria:
- • Documented pseudoaneurysm \> 1 cm within the WON.
- • Subject unable or unwilling to provide informed consent.
- • Intervening gastric varices or unavoidable blood vessels within the WON access tract (visible using endoscopy or endoscopic ultrasound).
- • Coagulation disorders or anti-coagulant therapy which cannot be discontinued (aspirin allowed).
- • Any condition that in the opinion of the Investigator would create an unsafe clinical situation or stent placement that would not allow the patient to safely undergo an endoscopic procedure.
- • Pregnant or lactating women or women of childbearing potential who do not employ a reliable method of contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the duration of study participation.
- • Patient is enrolled in another trial that could interfere with the endpoint analyses of this trial.
- • Prior necrosectomy on existing collection.
- • Greater than 2 pancreatic / extra-pancreatic fluid collections.
About Erasmus Medical Center
Erasmus Medical Center, located in Rotterdam, Netherlands, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution within the Erasmus University Rotterdam, the center integrates cutting-edge scientific inquiry with comprehensive patient care, focusing on a wide range of medical specialties. With a strong emphasis on multidisciplinary collaboration, Erasmus Medical Center aims to translate research findings into tangible clinical applications, enhancing treatment options and improving patient outcomes. The institution is dedicated to conducting ethical and rigorous clinical trials that contribute to the global body of medical knowledge and foster advancements in personalized medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Birmingham, Alabama, United States
Nieuwegein, , Netherlands
San Francisco, California, United States
Frankfurt, , Germany
Roma, , Italy
Amsterdam, , Netherlands
Amsterdam, , Netherlands
Hvidovre, , Denmark
Düsseldorf, , Germany
Milano, , Italy
Manchester, , United Kingdom
Patients applied
Trial Officials
Marco Bruno, MD PhD
Principal Investigator
Erasmus Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials